Login / Signup

Survival with Cemiplimab in Recurrent Cervical Cancer.

Krishnansu S TewariBradley J MonkIgnace VergoteAustin MillerAndreia Cristina de MeloHee-Seung KimYong Man KimAlla LisyanskayaVanessa SamouëlianDomenica LorussoFernanda DamianChih-Long ChangEvgeniy A GotovkinShunji TakahashiDaniella RamoneJoanna PikielBeata Maćkowiak-MatejczykEva M Guerra AlíaNicoletta ColomboYulia MakarovaDanny RischinStephanie LheureuxKosei HasegawaKeiichi FujiwaraJingjin LiShaheda JamilVladimir JankovicChieh-I ChenFrank SeebachDavid M WeinreichGeorge D YancopoulosIsrael LowyMelissa MathiasMatthew G FuryAna Oakninnull null
Published in: The New England journal of medicine (2022)
Survival was significantly longer with cemiplimab than with single-agent chemotherapy among patients with recurrent cervical cancer after first-line platinum-containing chemotherapy. (Funded by Regeneron Pharmaceuticals and Sanofi; EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 ClinicalTrials.gov number, NCT03257267.).
Keyphrases
  • locally advanced
  • free survival
  • rectal cancer
  • chemotherapy induced